effect
drug
avail
treat
influenza
neuraminidas
na
inhibitor
provid
import
addit
measur
control
influenza
viru
infect
howev
sinc
emerg
na
inhibitorresist
virus
may
compromis
clinic
util
class
antiinfluenza
agent
import
develop
new
antiinfluenza
agent
target
differ
region
na
respons
sensit
na
inhibitor
could
use
treat
na
inhibitorsresist
isol
oligodeoxynucleotid
multimer
aggreg
suppress
replic
influenza
virus
except
wsn
suppress
viral
replic
depend
gterad
multim
format
rang
suppress
viral
replic
late
stage
includ
viru
assembl
releas
infect
cell
much
larger
initi
stage
viral
attach
entri
suppress
na
activ
influenza
virus
furthermor
replac
na
gene
apuerto
viral
replic
inhibit
late
stage
na
gene
wsn
viral
replic
inhibit
elimin
suppress
show
addit
antiinfluenza
effect
oseltamivir
also
effect
vivo
result
suggest
influenza
viru
na
mainli
contributs
viru
releas
infect
cell
late
stage
addit
administr
virusinfect
mice
suppress
viral
replic
weight
loss
clinic
applic
could
consid
influenza
virus
caus
annual
epidem
occasion
pandem
human
result
high
mortal
primarili
elderli
highrisk
popul
hayden
whitley
monto
vaccin
antivir
drug
two
avail
strategi
prevent
control
influenza
viru
infect
usual
take
month
prepar
vaccin
case
pandem
influenza
period
pandem
spread
infect
human
caus
great
damag
economi
neumann
et
al
lag
phase
take
antivir
drug
avail
approach
control
treat
influenza
viru
infect
moreov
influenza
viru
infect
complet
prevent
vaccin
antivir
drug
still
necessari
therapeut
treatment
influenza
nistalvillan
garciasastr
date
effect
drug
treat
influenza
neuraminidas
na
inhibitor
na
inhibitor
includ
oseltamivir
zanamivir
provid
import
addit
measur
control
influenza
boltz
et
al
antivir
drug
target
activ
center
influenza
viru
na
molecul
amino
acid
larg
conserv
among
influenza
b
virus
colman
et
al
howev
emerg
na
inhibitorresist
virus
result
drug
use
due
circul
natur
variant
may
compromis
clinic
util
class
antiinfluenza
agent
haug
et
al
van
der
vri
et
al
polyanion
dextran
sulfat
ds
heparin
prove
broad
spectrum
antivir
activ
envelop
virus
human
immunodefici
viru
hiv
herp
virus
vesicular
stomat
viru
baba
et
al
hosoya
et
al
mechan
inhibit
viru
replic
polyanion
attribut
inhibit
viru
adsorpt
cell
membran
andor
viru
envelop
fusion
endosom
membran
mitsuya
et
al
arnberg
et
al
luschermattli
et
al
influenza
viru
sever
studi
demonstr
suppress
viral
replic
ds
caus
inhibit
hemagglutinin
ha
activ
play
role
viral
fusion
process
earli
stage
infect
luschermattli
gluck
ramalhosanto
de
lima
recent
report
ds
also
suppress
na
activ
releas
infect
cell
late
stage
replic
result
suppress
viral
replic
yamada
et
al
sinc
ds
neg
charg
chang
viral
surfac
posit
neg
charg
ad
ds
may
play
role
suppress
viral
replic
moulard
et
al
yamada
et
al
bacteri
synthet
oligodeoxynucleotid
odn
contain
unmethyl
cpg
dinucleotid
specif
sequenc
context
cpg
trigger
vertebr
immun
system
activ
tolllik
receptor
krieg
klinman
result
innat
immun
respons
limit
earli
spread
infecti
organ
promot
develop
adapt
immun
optim
sequenc
activ
vari
among
speci
bauer
et
al
least
four
type
cpg
odn
differ
backbon
sequenc
immunostimulatori
properti
vollmer
krieg
dtype
also
call
cpg
odn
typic
compris
one
palindrom
cpg
motif
phosphodiest
po
backbon
phosphorothio
ps
poli
g
tail
increas
resist
nucleas
activ
plasmacytoid
dendrit
cell
pdc
produc
larg
amount
interferon
ifn
fail
induc
pdc
matur
bcell
activ
krug
verthelyi
et
al
three
type
odn
consist
ps
backbon
ktype
also
call
b
cpg
odn
contain
nonpalindrom
multipl
cpg
motif
strongli
activ
b
cell
produc
interleukin
il
pdc
matur
bare
produc
ifna
hartmann
krieg
verthelyi
et
al
c
ptype
cpg
odn
contain
one
two
palindrom
cpg
sequenc
respect
activ
b
cell
like
ktype
pdc
like
dtype
although
c
cpg
odn
induc
weaker
ifna
product
compar
ptype
cpg
odn
hartmann
krieg
marshal
et
al
samulowitz
et
al
dtype
cpg
odn
character
core
sequenc
singl
palindrom
purinepyrimidinecpgpurinepyrimidin
motif
flank
side
selfcomplementari
base
po
backbon
structur
render
sequenc
flexibl
allow
format
stemeloop
conform
andor
form
dimer
dtype
odn
molecul
verthelyi
et
al
addit
dtype
odn
end
poli
g
motif
verthelyi
et
al
known
selfassoci
via
hoogsteen
basepair
form
parallel
quadruplex
structur
call
gtetrad
panyutin
et
al
costa
et
al
report
ds
suppress
replic
influenza
virus
electr
interact
viral
protein
sulfat
contain
neg
charg
yamada
et
al
result
rais
hypothesi
odn
well
ds
may
suppress
viral
replic
well
known
exist
po
bond
result
electr
neg
charg
odn
therefor
examin
synthet
odn
candid
antiinfluenza
compound
present
studi
found
dtype
odn
suppress
na
activ
releas
infect
cell
late
stage
infect
madinedarbi
canin
kidney
mdck
cell
maintain
minimum
essenti
medium
mem
nissui
pharmaceut
supplement
mgml
lglutamin
fetal
calf
serum
fc
mgml
gentamicin
human
embryon
kidney
cell
maintain
dulbecco
modifi
eagl
medium
dmem
nissui
pharmaceut
supplement
mgml
lglutamin
fc
mgml
gentamicin
influenza
virus
panama
wyom
obtain
dr
odagiri
nation
institut
infecti
diseas
japan
human
pandem
viru
isol
osaka
japan
patient
exhibit
mild
influenza
symptom
recov
uraki
et
al
describ
previous
sakab
et
al
puerto
wsn
gener
plasmidbas
revers
genet
neumann
et
al
horimoto
et
al
plasmid
contain
genom
segment
wsn
four
wsn
protein
express
plasmid
encod
pa
np
kindli
provid
dr
kawaoka
univers
wisconsin
usa
reassort
virus
wsn
recombin
virus
mutat
na
gene
describ
previous
yamada
et
al
yamada
et
al
synthet
odn
gpc
synthes
purifi
genedesign
japan
list
tabl
diethylaminoethyldextran
hydrochlorid
dea
mean
molecular
weight
purchas
mp
biomed
dextran
mean
molecular
weight
purchas
polysci
oseltamivir
carboxyl
purchas
chemscen
determin
efficaci
compound
viabil
mdck
cell
perform
mtt
assay
mtt
cell
viabil
assay
kit
biotium
brief
confluent
monolay
mdck
cell
tissu
cultur
plate
wash
pb
twice
ml
viru
dilut
medium
vdm
mem
supplement
mg
ml
lglutamin
mgml
gentamicin
bovin
serum
albumin
bsa
sever
concentr
compound
appli
monolay
incub
c
everi
h
post
infect
hpi
mtt
assay
perform
accord
manufactur
instruct
cell
viabil
express
percentag
mtt
reduct
assign
valu
absorb
nontreat
mdck
cell
confirm
coumpound
abil
decreas
viabil
mdck
cell
fig
furthermor
ad
oseltamivir
chang
viabil
mdck
cell
fig
stock
viru
prepar
recombin
virus
collect
transfect
cell
grown
mdck
cell
describ
previous
barman
et
al
briefli
mdck
cell
infect
virus
multipl
infect
moi
use
vdm
infect
mdck
cell
incub
c
viru
growth
medium
vgm
mem
contain
mem
vitamin
solut
invitrogen
mm
hepe
ph
mgml
gentamicin
bsa
mgml
crystal
trypsin
sigmaealdrich
supernat
collect
cytopath
effect
observ
tenfolddilut
virus
ml
mem
bsa
appli
confluent
monolay
mdck
cell
plate
incub
c
h
unbound
virus
remov
cell
wash
mem
cell
overlaid
ml
vgm
contain
agaros
sigmaealdrich
mgml
crystal
trypsin
sigmaealdrich
incub
c
cell
fix
formaldehyd
stain
crystal
violet
solut
stain
odn
sampl
dilut
pb
mgml
drop
formvarcarbonco
grid
neg
stain
drop
wtvol
uranyl
acet
ph
place
grid
left
air
dri
grid
examin
magnif
electron
microscop
hitachi
japan
na
activ
measur
use
nastar
influenza
neuraminidas
inhibitor
resist
detect
kit
appli
biosystem
accord
manufactur
instruct
virus
cell
cultur
supernat
dilut
appropri
preincub
variou
concentr
min
room
temperatur
incub
nastar
substrat
min
addit
nastar
acceler
chemiluminesc
signal
measur
rate
swell
glomaxmulti
detect
system
promega
rel
na
activ
determin
mean
percent
triplic
well
calcul
control
valu
obtain
absenc
mdck
cell
infect
wsn
moi
c
eight
hpi
cultur
wash
three
time
vdm
without
mgml
ad
cell
thirteen
hpi
cell
fix
glutaraldehyd
paraformaldehyd
phosphat
buffer
pb
ph
postfix
oso
pb
ph
embed
epon
electron
microscopi
scienc
ultrathin
section
cut
em
ultramicrotom
leica
microsystem
observ
magnif
electron
microscop
eightweek
old
femal
balbc
mice
japan
slc
anesthet
inocul
intranas
plaqu
form
unit
pfu
dilut
ml
pb
indic
time
mice
anesthet
inocul
intranas
inocul
volum
ml
compound
dilut
pb
h
infect
lung
excis
homogen
use
multibead
shocker
yasui
kikai
japan
accord
manufactur
protocol
viral
titer
lung
homogen
estim
use
plaqu
assay
mortal
statu
weight
loss
mice
assess
daili
day
thereaft
nation
institut
biomed
innov
author
anim
studi
approv
number
experi
perform
accord
guidelin
committe
fisher
exact
test
perform
use
softwar
om
tokyo
japan
evalu
differ
group
mortal
experi
analyz
data
experi
nonparametr
student
ttest
use
p
valu
consid
signific
first
examin
whether
plaqu
format
infect
mdck
cell
influenza
virus
inhibit
odn
tabl
odn
contain
cpg
motif
activ
immun
respons
puig
et
al
compris
immunosuppress
motif
ttaggg
block
signal
kaminski
et
al
influenza
viru
strain
panama
inocul
onto
mdck
cell
incub
cell
wash
three
time
mem
overlaid
vgm
contain
agaros
presenc
absenc
odn
shown
fig
number
plaqu
remark
decreas
presenc
panamainfect
cell
contrast
inhibit
significantli
plaqu
format
strain
moder
effect
therefor
focus
examin
inhibitori
effect
influenza
virus
shown
fig
suppress
plaqu
format
infect
mdck
cell
wyom
hand
plaqu
format
wsn
significantli
suppress
next
determin
whether
also
suppress
continu
growth
viru
strain
whose
plaqu
format
inhibit
mdck
cell
infect
wsn
panama
presenc
absenc
continu
incub
presenc
titer
panama
whose
plaqu
format
suppress
less
without
hpi
fig
contrast
significantli
affect
viral
growth
wsn
whose
plaqu
format
suppress
result
indic
viru
strain
whose
plaqu
format
suppress
also
show
growth
suppress
infect
cell
without
agaros
sinc
neg
charg
po
backbon
examin
whether
ad
dea
posit
charg
affect
suppress
influenza
viru
replic
mdck
cell
infect
incub
vgm
contain
agaros
presenc
mgml
variou
concentr
dea
shown
fig
dea
dosedepend
recov
suppress
plaqu
format
contrast
ad
mgml
dextran
neutral
charg
restor
plaqu
format
suppress
suggest
neutral
neg
charg
dea
disabl
inhibit
influenza
viru
replic
sinc
contain
unmethyl
cpg
dinucleotid
trigger
vertebr
immun
respons
activ
klinman
krieg
examin
whether
cpg
motif
would
affect
suppress
effect
plaqu
format
use
gpc
induc
activ
fig
show
gpc
also
suppress
influenza
viru
replic
indic
immun
respons
trigger
involv
suppress
effect
end
poli
g
motif
known
selfassoci
via
hoogsteen
basepair
form
parallel
quadruplex
structur
call
gtetrad
verthelyi
et
al
report
format
multim
necessari
dtype
odn
local
earli
transfer
receptorposit
endosom
signal
induc
ifna
monomer
sequenc
behav
competit
antagonist
wu
et
al
kerkmann
et
al
guiducci
et
al
thu
examin
whether
gtetrad
format
would
affect
suppress
effect
plaqu
format
use
two
odn
remov
end
poli
g
motif
replac
end
guanin
imped
gtetrad
format
tabl
fig
show
plaqu
format
suppress
result
suggest
gtetrad
format
requir
suppress
effect
although
compris
telomer
ttaggg
repeat
assum
antiparallel
gtetrad
structur
intramolecular
fold
balagurumoorthi
brahmachari
dtype
odn
abil
form
secondari
structur
aggreg
multimer
promot
presenc
guaninerich
wu
et
al
next
examin
whether
aggreg
odn
dilut
pb
observ
negativestain
em
shown
fig
gpc
selfassembl
form
network
structur
howev
form
globular
structur
form
aggreg
result
indic
aggreg
format
multim
necessari
gpc
inhibit
influenza
viru
replic
determin
stage
viral
replic
inhibit
perform
time
cours
studi
inhibitori
effect
sinc
take
h
influenza
virus
produc
progeni
virus
viru
absorpt
four
treatment
interv
cover
whole
life
cycl
influenza
virus
absorpt
progeni
product
use
disclos
time
frame
exert
maxim
effect
appli
interv
cell
wash
three
time
mem
specif
time
point
follow
treatment
fresh
compoundfre
vdm
continu
maintain
vgm
without
mgml
c
everi
hpi
cultur
supernat
collect
viru
titer
supernat
assess
plaqu
assay
bar
repres
mean
standard
deviat
three
independ
sampl
ad
treat
cell
harvest
hpi
viru
yield
determin
measur
viru
titer
everi
cultur
shown
fig
appar
inhibit
viru
replic
observ
infect
cell
treat
interv
hpi
correspond
late
step
influenza
viru
replic
bud
releas
infect
cell
case
treatment
interv
hpi
moder
inhibit
ca
observ
infect
cell
howev
treatment
interv
hpi
inhibit
viru
yield
compar
control
group
result
suggest
inhibit
earli
late
step
viral
replic
thu
next
examin
suppress
effect
sever
strain
earli
late
step
viral
replic
sever
decreas
viral
replic
observ
panama
wyom
cell
present
late
stage
wherea
littl
reduct
viral
growth
wsn
observ
fig
c
result
suggest
mainli
suppress
late
stage
viral
growth
includ
viral
assembl
releas
infect
cell
na
promot
releas
progeni
virus
infect
host
cell
destroy
sialic
acid
receptor
host
cell
virus
contribut
releas
progeni
virus
infect
cell
late
stage
infect
pales
et
al
pales
compan
thu
examin
whether
na
activ
suppress
latestagesensit
influenza
viru
strain
fig
concentr
inhibit
na
activ
panama
much
lower
requir
inhibit
na
activ
wsn
without
mgml
gpc
c
c
gpc
selfassembl
form
network
structur
one
mgml
gpc
dilut
pb
examin
negativestain
em
magnif
result
suggest
suppress
enzymat
activ
na
influenza
virus
addit
em
experi
show
treatment
induc
viral
aggreg
cell
surfac
wherea
aggreg
observ
wsninfect
cell
fig
result
indic
caus
viral
aggreg
infect
cell
surfac
inhibit
enzymat
activ
na
thu
releas
virus
infect
cell
previous
report
na
mainli
respons
inhibit
ds
use
seri
construct
reassort
dssensit
dsresist
wsn
strain
yamada
et
al
examin
sensit
plaqu
assay
mdck
cell
fig
plaqu
format
reassort
contain
na
protein
wsn
na
contain
ha
protein
wsn
ha
inhibit
furthermor
plaqu
format
reassort
contain
na
wsn
protein
na
inhibit
contain
ha
wsn
protein
ha
inhibit
result
indic
na
main
determin
differ
sensit
wsn
strain
also
report
critic
amino
acid
na
dssensit
basic
amino
acid
correspond
amino
acid
supplementari
fig
yamada
et
al
examin
plaqu
format
seri
recombin
virus
na
singl
mutat
found
dsresist
virus
plaqu
undetect
mdck
cell
infect
recombin
virus
na
presenc
howev
mdck
cell
infect
recombin
virus
na
small
plaqu
detect
na
virusinfect
mdck
cell
plaqu
moder
size
detect
presenc
fig
result
suggest
basic
amino
acid
specif
na
import
similarli
dssensit
addit
effect
oseltamivir
mainli
target
na
larg
differ
target
site
oseltaminir
na
inhibitor
bind
activ
site
viral
na
molecul
thu
examin
whether
oseltamivir
effect
recombin
virus
whether
oseltamivirresist
viru
sensit
use
recombin
viru
resist
oseltamivir
fig
carr
et
al
plaqu
undetect
mdck
cell
infect
oseltamivirresist
presenc
cell
infect
presenc
oseltaminir
next
found
oseltamivir
addit
effect
result
ad
mg
ml
nm
oseltamivir
decreas
size
plaqu
ad
compound
decreas
greater
fig
moreov
oseltamivir
show
addit
effect
na
vitro
na
activ
assay
fig
result
suggest
mechan
action
differ
oseltamivir
show
addit
antivir
effect
oseltamivir
examin
whether
inhibit
viru
replic
vivo
infect
mice
intranas
subleth
dose
pretreat
mice
intranas
gpc
h
infect
treat
gpc
oseltamivir
pb
hpi
shown
fig
mean
weight
loss
mice
treat
gpc
infect
significantli
less
pbstreat
mice
effect
similar
case
oseltamivir
treatment
sinc
mice
receiv
infect
exhibit
weight
loss
earli
time
infect
dpi
observ
mice
receiv
pb
gpc
infect
suppos
activ
immun
respons
togeth
activ
immun
respons
influenza
viru
infect
led
specif
weight
loss
contrast
treatment
infect
significantli
inhibit
weight
loss
mice
treatment
gpc
infect
less
effici
consist
improv
outcom
gpc
oseltamivir
significantli
reduc
titer
lung
homogen
examin
hpi
fig
studi
show
short
odn
contain
neg
charg
po
backbon
significantli
suppress
replic
sever
influenza
viru
strain
also
found
mainli
inhibit
replic
influenza
virus
late
step
depend
na
activ
previous
report
na
main
target
ds
yamada
et
al
similar
pattern
suppress
influenza
viru
replic
found
mutat
na
chang
addit
na
contain
mutat
partial
resist
fig
result
suggest
na
main
target
well
ds
use
molecular
dynam
simul
influenza
na
extend
conform
shift
na
observ
amaro
et
al
amaro
et
al
demonstr
na
region
open
much
larger
extent
anticip
prior
xray
structur
analys
systemat
explor
develop
potent
chemic
divers
inhibitor
report
novel
smallmolecul
inhibitor
inhibit
viral
replic
virus
compound
predict
establish
hydrogen
bond
residu
also
suggest
anoth
bind
site
within
pocket
form
could
access
new
inhibitor
therefor
target
novel
antiinfluenza
drug
oseltamivir
carboxyl
na
inhibitor
bind
activ
site
viral
na
frequent
use
treat
influenza
howev
mark
increas
oseltamivirresist
isol
report
strain
becom
preval
worldwid
haug
et
al
hurt
et
al
show
recombin
viru
resist
oseltamivir
sensit
sensit
oseltamivir
oseltamivir
addit
effect
fig
result
indic
region
na
respons
oseltamivirsensit
differ
might
use
treatment
infect
oseltamivirresist
viru
howev
sinc
determin
whether
reduc
replic
recent
oseltamivirresist
viru
strain
studi
futur
case
treat
aid
combin
therapi
use
two
drug
simultan
inhibit
hiv
replic
develop
lower
toxic
decreas
dosag
individu
compound
approach
reduc
risk
develop
drug
resist
maintain
synergist
antivir
activ
de
clercq
would
major
advanc
treatment
influenza
viru
infect
ktype
odn
consist
ps
backbon
amphipath
polyanion
psoligonucleotid
on
sequenceindepend
antivir
activ
gao
et
al
yao
et
al
fennewald
et
al
pson
prevent
viral
attach
entri
via
interact
viral
glycoprotein
herp
simplex
viru
hsv
hepat
c
viru
vaillant
et
al
guzman
et
al
matsumura
et
al
howev
antivir
activ
pson
depend
length
hydrophob
on
known
phosphorothio
increas
hydrophob
on
agraw
et
al
increas
hydrophob
pson
contribut
inhibitori
activ
fusion
entri
longer
pson
base
greater
hydrophob
potent
block
hydrophob
interact
involv
sixhelix
bundl
format
inhibit
cellecel
fusion
shorter
pson
base
vaillant
et
al
antivir
cultur
supernat
mdck
cell
contain
influenza
viru
treat
without
follow
measur
na
activ
sampl
describ
materi
method
rel
na
activ
determin
mean
percent
given
control
valu
line
repres
mean
standard
deviat
three
independ
sampl
b
mdck
cell
infect
wsn
moi
c
viral
adsorpt
vdm
without
ad
cell
hpi
cultur
wash
three
time
vdm
without
mg
ml
ad
cell
hpi
cell
process
em
magnif
activ
pson
duck
hepat
b
viru
infectioni
also
size
depend
pson
base
length
display
highest
activ
noordeen
et
al
thu
specul
longer
psodn
base
would
antiinfluenza
activ
short
gt
richodn
assum
gtetrad
structur
intramolecular
fold
potent
inhibitor
hiv
bishop
et
al
inhibit
integras
jing
et
al
moreov
gt
rich
base
psodn
potent
antivir
activ
hsv
thought
mediat
conform
chang
viral
glycoprotein
gb
shogan
et
al
inhibit
significantli
replic
influenza
virus
multimer
form
aggreg
fig
thu
result
suggest
contrast
odn
abil
inhibit
hsv
inhibit
influenza
virus
odn
need
mutimer
aggreg
report
ggtgcatcgatgcagggggg
phosphorothio
sequenc
two
ps
linkag
end
poli
g
track
consist
extrem
heterogen
mixtur
secondari
structur
dpb
portion
molecul
exist
highord
aggreg
contain
strand
marshal
et
al
know
spontan
format
nanoparticl
respons
inhibit
influenza
virus
howev
antivir
activ
ds
influenza
viru
increas
molecular
weight
increas
level
molecular
weight
increas
hosoya
et
al
result
may
suggest
size
multimer
odn
import
report
intranas
pretreat
synthet
agonist
protect
mice
lethal
influenza
pneumonia
intranas
pretreat
agonist
alon
result
protect
tuvim
et
al
also
report
intranas
pretreat
agonist
poli
c
lesser
extent
synthet
agonist
protect
mice
lethal
coronaviru
infect
intranas
pretreat
ifna
ifnb
protect
mice
lethal
influenza
pneumonia
zhao
et
al
thu
plausibl
agonist
gpc
induc
cytokin
type
ifn
activ
protecr
mice
influenza
viru
infect
howev
mice
treat
gpc
without
infect
reassort
wsn
c
absenc
incub
agaros
without
mgml
black
white
bar
repres
gene
wsn
respect
b
mdck
cell
infect
recombin
virus
absenc
maintain
agaros
without
mgml
c
unmethyl
cpg
infect
viral
titer
lung
homogen
reduc
bodi
weight
loss
minim
suggest
immun
respons
lead
cytokin
express
involv
protect
effect
gpc
although
treatment
infect
reduc
viral
titer
lung
homogen
gpc
mice
receiv
infect
exhibit
larger
weight
loss
gpctreat
mice
earli
time
infect
fig
consequ
inappropri
activ
detriment
host
contribut
pathogenesi
bacteri
septic
shock
autoimmun
diseas
system
lupu
erythematosu
ehler
ravetch
thu
think
gpc
without
cpg
motif
would
better
candid
influenza
viru
treatment
contain
cpg
motif
conclus
ligand
inhibit
na
activ
replic
influenza
virus
suggest
basic
amino
acid
na
involv
show
addit
effect
oseltamivir
gpc
reduc
viral
replic
lung
infect
mice
thu
could
use
combin
avail
na
inhibitor
treat
influenza
viru
infect
sinc
well
toler
clinic
trial
nonhuman
primat
leishmania
malaria
vaccin
verthelyi
et
al
tougan
et
al
vivo
clinic
studi
warrant
mdck
cell
treat
without
mgml
nm
oseltamivir
follow
measur
na
activ
sampl
rel
na
activ
determin
mean
percent
given
control
valu
line
repres
mean
standard
deviat
three
independ
sampl
fig
effect
mous
eightweekold
femal
balbc
mice
treat
mgkg
gpc
h
mgkg
gpc
oseltamivir
pb
h
intranas
infect
pfu
viru
weight
loss
monitor
daili
day
n
micegroup
b
obtain
viru
titer
lung
isol
hpi
homogen
viru
titer
determin
mdck
cell
titer
express
pfulung
homogen
n
micegroup
